Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
No patent data available. Pre-approval drugs may not have Orange Book listings.
5 competitors in Psoriasis
View Full LandscapeSource: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Ilumetri
Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
View on EMAColorectal Adenoma
Acute Hematogenous Osteomyelitis
Dyslipidemia
Type 2 Diabetes Mellitus (T2DM)
Non Small Cell Lung Cancer (NSCLC)